ABL provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. ABL combines its expertise in translational science together with operational excellence to solve the challenging product development problems that are often faced by our clients as they bring their life-changing technologies to the world. With cGMP facilities located in the U.S. and Europe, ABL is well positioned to provide comprehensive development and manufacturing support for protein and virus production utilizing single-use bioreactor platforms and other disposable technologies. ABL provides our clients with a fully integrated solution that includes cell line and process development, GMP manufacturing, QC release testing and QA/Regulatory support. ABL’s contract research teams have decades of experience with immunoassays, developing custom assays and panels to support human clinical trials and preclinical animal studies. We routinely work with clients to design and run immunogenicity studies, biomarker analyses and other evaluations to better understand the impact of cutting-edge therapies: the mechanism of action, correlates of protection, pharmacokinetic/pharmacodynamics studies and other critical safety and efficacy data. ABL is a subsidiary of the Institut Mérieux, a global organization committed to serving medicine and public health across the globe.
Phone: 33, (0)4, 37, 70, 87, 00
Fax: 33, (0)4, 37, 70, 67, 98
Web: https://ablinc.com
Add：Batiment Domilyon, Centre d’Infectiologie 321 avenue Jean Jaurès 69007, Lyon
想要下载更多资料，请您添加微信了解详情！
微信号：csco2022
公众号：康安医药咨询
